Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The incidence of the three MAF variants in BRAF-mutant primaries was similar, whereas the high MAF cases were found to be increased in metastases.
|
31391014 |
2019 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Physician awareness of the spectrum of secondary malignancies associated with BRAF inhibitor treatment will support their early detection and treatment.
|
28796396 |
2017 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
One-hundred-thirteen melanoma metastases underwent microarray analysis and BRAF and NRAS genotyping.
|
25174651 |
2015 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thirty-three samples (7 of 25 primaries, 15 of 25 regional metastases, 5 of 25 nodal metastases, and 6 of 10 distant metastases) harbored the V599E B-RAF mutation (39%), 12 contained a Q61R N-RAS mutation and 5 a Q61K N-RAS mutation.
|
14695143 |
2003 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Correlation of VE1 immunohistochemistry and BRAF sequencing revealed a perfect match for both papillary thyroid carcinomas and melanoma metastases.
|
21638088 |
2011 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Therefore, we established a large collection of patient-derived xenografts (PDXs), derived from BRAF(V600E), NRAS(Q61), or BRAF(WT)/NRAS(WT) melanoma metastases prior to treatment with BRAF inhibitor and after resistance had occurred.
|
27320919 |
2016 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In our study of 51 primary nodular melanomas and 18 paired metastases, we found mutations in BRAF (codon 600, previously denoted 599) in 15 primary tumors (29%) and eight metastases (44%).
|
16098042 |
2005 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites.
|
23533235 |
2013 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we analyse 20 BRAF(V600)-mutant melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response.
|
25452114 |
2014 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAF(V600E) in the thoracic metastases of sporadic mCRC patients has not been evaluated until now.
|
24798160 |
2014 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Discordance in BRAF mutation status was found only in four patients, involving all three patients in whom sentinel lymph node (SLN) metastases were sampled.
|
26020488 |
2015 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases.
|
17199440 |
2006 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients were matched according to somatic <i>BRAF</i>V600E mutation (80 BRAF+ and 80 BRAF- patients) and to the presence (LN+, 40 patients each group) or absence (LN, 40 patients each group) of neck lymphnode metastases.
|
30374428 |
2018 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases.
|
29120401 |
2017 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In multiple regression analyses, panitumumab treatment, liver-only metastases and WT BRAF status were consistently associated with improved ETS and DpR outcomes.
|
29080924 |
2018 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations of the BRAF gene were correlated to superficial spreading melanoma (odds ratio = 1.31), localization in the torso (odds ratio = 1.42) and presence of metastases.
|
31274706 |
2020 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK.
|
20605766 |
2010 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
BRAF-positive primary tumors (P=0.02) and metastases (P=0.01) exhibited increased plasmacytoid dendritic cell numbers compared with BRAF-negative tumors.
|
30299387 |
2019 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigate the effect of radioactive iodine (RAI) therapy on the clinical outcome in PTC patients with the BRAF(V600E) mutation without distant metastases.
|
26780618 |
2016 |
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Transcriptome profiling revealed that transcription factor HMGA2, previously unrecognized in melanoma pathogenesis, is significantly upregulated in primary melanoma and metastases (P-values=1.2 × 10(-7) and 9 × 10(-5)) compared with N. HMGA2 overexpression is associated with BRAF/NRAS mutations (P=0.0002).
|
23633021 |
2013 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined TTF1 nuclear expression in the context of adverse pathological features, disease recurrence, and BRAF status in papillary thyroid carcinomas with (n = 182) and without (n = 303) nodal metastases.
|
31229486 |
2019 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF V600E gene mutation was documented in this lesion, and the patient received vemurafenib, with dramatic improvement noted on positron emission tomography scan after 2 months of treatment, soon followed by development of extensive metastases, including to brain.
|
23715079 |
2013 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genomic DNA from a total of 749 tumor samples (451 primary tumors and 298 metastases) in 513 consecutively-collected patients with advanced melanoma (AJCC stages III and IV) was screened for mutations in exon 15 of BRAF gene and, at lower extension (354/513; 69%), in the entire coding DNA of NRAS gene by automated direct sequencing.
|
23987572 |
2013 |
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRAF mutation in primary tumor might be a promising molecular marker to predict the status of I uptake in distal metastases.
|
24978326 |
2014 |
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type.
|
29076951 |
2017 |